Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan.
The aim of this study was to evaluate the medium-term effects of the selective AT1-blocker irbesartan on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg for 30 days. Plasma ANP levels increased by 15.7% despite the drop in blood pressure and the slight decrease of atrial and ventricular diameters. These findings indicate that AT,-blockers like irbesartan exert part of their antihypertensive action by increasing ANP plasma levels.
Kotridis
Panagiotis
P
Department of Second Cardiology, Medical School, Aristotle University of Thessaloniki, Greece.
Kokkas
Basile
B
Karamouzis
Michalis
M
Sakadamis
George
G
Kanonidis
Ioannis
I
Dadous
George
G
Karantona
Chrisoula
C
Gouli
Olga
O
Karadoumanis
Joshef
J
Papadopoulos
Pavlos C
PC
Papadopoulos
Constantine L
CL
D000328:Adult; D000368:Aged; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D009320:Atrial Natriuretic Factor / Q000097:blood*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles / Q000627:therapeutic use*
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D009320:Atrial Natriuretic Factor; D000077405:Irbesartan